Overview
To observe the PFS of yttrium [90Y] microsphere injection combined with FOLFIRI and bevacizumab in second-line treatment of CRLM.
Description
This study is a prospective, multicenter, observational, cohort study to observe the efficacy and safety of selective internal radiation therapy (SIRT) with yttrium [90Y] microsphere injection combined with FOLFIRI and bevacizumab as second-line therapy in patients with colorectal cancer liver metastases.
Eligibility
Inclusion Criteria:
- 18 years old≤ age ≤ 75 years old
- Voluntarily signed informed consent
- Patients with liver metastases of colorectal cancer, colorectal cancer lesions have resection, liver metastases limited to a single lobe
- The liver tumor progresses after first-line treatment, and FOLFIRI combined with bevacizumab therapy is planned
- On the assessment of the clinician, the patient was eligible for yttrium [90Y] microspheres injection, and treatment with yttrium [90Y] microspheres injection was planned
- KRAS mutant
- ECOG PS: 0-1
- Child Pugh score ≤7
- Adequate level of organ function：a) Hematology: Neutrophils (ANC) ≥1.5×109/L, hemoglobin (HB) ≥90 g/L, platelets (PLT) ≥75×109/L；b) Liver function: albumin > 3 g/dL; ALT and AST≤ 5 x ULN; TBIL < 34.0 μmol/L；c) Renal function: serum creatinine ≤176.8 μmol/L or endogenous creatinine clearance > 50 mL/min；d) Coagulation function: INR≤1.2.
Exclusion Criteria:
- After liver metastasis was diagnosed, the liver underwent external radiation therapy and transhepatic arterial chemoembolization
- Patients with extrahepatic metastases
- Pregnant and lactating women
- History of severe arrhythmia or heart failure
- Other researchers considered it inappropriate to participate in this study